Similarly, miR-22 has been implicated in breast cancer progression [204], epithelial ovarian cancer [205], and in prostate cancer, due to its interaction with PTEN [206], suggesting its role as a tumor suppressor [207]. This evidence concerns the gene PTEN and breast carcinoma.